The National Institute on Aging (NIA) awarded a $842,175 Project Grant under the Aging Research program (CFDA 93.866) to the J. David Gladstone Institutes in San Francisco, CA. The grant, awarded on December 15, 2024, will fund research to explore the role of the NOX2 enzyme in mediating Alzheimer's disease (AD) pathologies, including network hyperactivity, glucose hypometabolism, and accumulation of amyloid-beta and tau proteins. The research aims to assess the therapeutic efficacy of a novel...
This Project Grant award from the National Institute on Aging's (NIA) Aging Research program (CFDA 93.866) provides $3,038,050 to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University to study the molecular mechanisms of Alzheimer's disease. The funded research aims to discover a novel oxidative stress pathway that targets microglia, the immune cells in the brain, leading to their dysfunction and detrimental consequences in Alzheimer's disease. The goal is to develop...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $500,000.00 to Alzarrok Bio LLC to develop a peptide-based multi-target drug for Alzheimer's disease (AD). The goal is to demonstrate the in vivo efficacy of the drug candidate, ALZ100, in inhibiting neuroinflammation and neurodegeneration in an AD mouse model. The project will first determine the therapeutic concentration of ALZ100 in the brain and then evaluate its effects on key...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $994,436.00 to Transchromix LLC to develop novel brain-penetrant drugs for treating Alzheimer's disease (AD). The key products and services being delivered include: Discovering a noncanonical, translation regulatory function of the histone methyltransferase G9A in AD pathogenesis using a chromatin-activity-based chemoproteomic (ChAC) approach to dissect AD heterogeneity. Deducing the mechanism...
This Project Grant award from the National Institute on Aging (NIA), part of the Aging Research program (CFDA 93.866), provides $622,086.00 to The Johns Hopkins University to conduct research on the role of the NOD2/RIPK2 signaling pathway in neuroinflammation and neurodegeneration in Alzheimer's disease. The 5-year project aims to elucidate the mechanisms of microglial activation by amyloid-beta oligomers, assess the involvement of the NOD2/RIPK2 pathway, determine the impact of selectively...
This Project Grant award, totaling $679,424, was provided by the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) to Colorado State University. The project aims to test the efficacy of a novel therapeutic targeting neuroinflammation for protecting against brain aging and Alzheimer's disease-related pathology. Specifically, the research will evaluate the role of the neuroinflammation mediators NF-kB and NLRP3 using a novel class of small molecule...
This Project Grant award from the National Institute on Aging provides $2,797,356 to the University of Pittsburgh to support research into DNA damage-induced inflammation and its brain-specific consequences from April 15, 2022 through March 31, 2025. The award is being made under the Aging Research program (CFDA 93.866), which aims to further the understanding of aging and age-related diseases. Specifically, the University of Pittsburgh will conduct research exploring cytoplasmic DNA (cytDNA) as...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $497,878 to Einsenca Inc. to conduct a first-in-human Phase 0 clinical study of the 18F-EH301 PET imaging agent. The goal is to assess the agent's ability to cross the human blood-brain barrier and validate its activation by myeloperoxidase (MPO) in the brains of patients with early-stage Alzheimer's disease. The award period runs from July 1, 2025 to June 30, 2026. This research aims to develop...
This federal Project Grant award of $238,500 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, will support research conducted by the University of California, San Diego (UCSD) to develop a new phosphorodiamidate morpholino oligonucleotide (PMO) therapeutic for treating Alzheimer's disease (AD). The research aims to create a highly effective PMO that can...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $499,883 to Degrome Therapeutics, Inc. to develop small-molecule degraders of the amyloid precursor protein (APP) as novel therapeutics for Alzheimer's disease (AD). The project aims to optimize lead APP degrader compounds to improve their potency, solubility, and blood-brain barrier permeability, with the goal of identifying the most promising candidates for further development and evaluation...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $636,000 to the University of Pittsburgh to investigate the use of NOX2 small molecule inhibitors as a potential therapeutic strategy for treating Alzheimer's disease (AD). The researchers aim to evaluate the ability of two novel, orally bioavailable, and blood-brain barrier penetrant NOX2 inhibitors (CPP11G and CPP11H) to improve cerebrovascular blood flow, reduce amyloid-beta deposition, and mitigate microglial inflammation in an established AD mouse model. If successful, these studies could have significant implications for the development of these NOX2 inhibitors as future AD treatments. The award period runs from September 1, 2024 to May 31, 2026.